เข้าสู่ระบบ สมัครสมาชิก

passive immunotherapy การใช้

ประโยคมือถือ
  • Administering monoclonal antibodies ( mAbs ) is a form of passive immunotherapy.
  • Passive immunotherapy has been tried for AIDS since 1985.
  • Passive immunotherapy has potential benefit in treatment of chikungunya.
  • Passive immunotherapies enhance existing anti-tumor responses and include the use of monoclonal antibodies, lymphocytes and cytokines.
  • Passive immunotherapy is effective in preventing or curing some other infections, even in people whose immune systems have been severely suppressed.
  • The authors said the study shows that the transfusion therapy, called passive immunotherapy, is safe and offers some clinical benefit.
  • Passive immunotherapy involves administration of anti-CHIKV hyperimmune human intravenous antibodies ( immunoglobulins ) to those exposed to a high risk of chikungunya infection.
  • Studies in animals using passive immunotherapy have been effective, and clinical studies using passive immunotherapy in those particularly vulnerable to severe infection are currently in progress.
  • Studies in animals using passive immunotherapy have been effective, and clinical studies using passive immunotherapy in those particularly vulnerable to severe infection are currently in progress.
  • Nevertheless, the authors of the study concluded that passive immunotherapy might be more effective in treating people infected with HIV, the virus that causes AIDS, than was previously believed.
  • Dr . Richard Haubrich, an AIDS researcher at the University of California, San Diego, cited experiments with passive immunotherapy in the United States and said the data on benefits were inconclusive.
  • Treatment using a transfusion of plasma from Ebola survivors, a form of  passive immunotherapy,  since it contains antibodies able to fight the virus, has been used with apparent success on a number of patients.
  • The plasma injections, known as passive immunotherapy, resulted in a threefold decrease in the cumulative number of such adverse events, said the French team, headed by Dr . J . J . Lefrere at the Hopital Saint-Antoine in Paris.